Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

Bioorganic & medicinal chemistry letters ·Vol. 20 ·No. 15 ·2010-08-01 ·Pages 4308-12

García-Echeverría C

Abstract

Over the past few years a number of components of the PI3K/mTOR pathway have been the subject of intense drug discovery activities both in pharmaceutical companies and in academia. This review article summarizes progress made in the identification and development of allosteric and ATP-competitive kinase inhibitors of mTOR and their potential therapeutic use in oncology.

MeSH Terms

Adenosine Triphosphate/metabolism Allosteric Regulation Antineoplastic Agents/chemistry,therapeutic use Humans Neoplasms/drug therapy Phosphatidylinositol 3-Kinase/metabolism Phosphoinositide-3 Kinase Inhibitors Protein Kinase Inhibitors/chemistry,therapeutic use Pyrimidines/chemistry,therapeutic use Signal Transduction TOR Serine-Threonine Kinases/antagonists & inhibitors,metabolism

Chemicals

Antineoplastic Agents Phosphoinositide-3 Kinase Inhibitors Protein Kinase Inhibitors Pyrimidines Adenosine Triphosphate Phosphatidylinositol 3-Kinase TOR Serine-Threonine Kinases

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

García-Echeverría Carlos

Oncology Drug Discovery, Sanofi-Aventis, Vitry-sur-Seine, France. Carlos.Garcia-Echeverria@sanofi-aventis.com

Article Info

Journal

Bioorganic & medicinal chemistry letters

Abbr.

Bioorg Med Chem Lett

ISSN

1464-3405

DOI

10.1016/j.bmcl.2010.05.099

carlos.garcia-echeverria@sanofi-aventis.com

Published

2010-08-01

Epub

2010-00-01

Pages

4308-12

Language

English

Region

England

NLM ID

9107377

Subset

External Links

PubMed source DOI: 10.1016/j.bmcl.2010.05.099 View journal details

Analysis Services

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.

Contact

WeChat Official Account